Skip to content
Menu

Danaher Corporation DHR

Full chart Compare
Set alert

Price alert · DHR

All alert types
220.36 USD -7.20 (-3.16%)

Regular-session close

221.31 +0.95 +0.43%

After hours · Nov 20, 7:37 PM ET

219.93 Day range 228.10
161.91 52-week range 242.05
YTD
-3.74%
1 year
-0.82%

5D -12.75 (-5.46%)

220225230MonTueWedThuFri220.76
Market cap
155.03B
Revenue (ttm)
25.61B
Profit margin
16.91%
EPS (ttm)
6.04
Shares out
703.53M
P/E ratio
36.48
Forward P/E
23.62
Dividend
1.60 (0.70%)
Ex-dividend date
Sep 30, 2026
YTD return
-3.74%
1-year return
-0.82%
Volume
3.99M
Avg volume
4.00M
Open
228.10
Previous close
227.56
Day's range
219.93 – 228.10
52-week range
161.91 – 242.05
Beta
0.80
Analysts
Strong Buy
Price target
259.90 (+17.9%)
Earnings date
Jan 27, 2027
50-day average
224.38

Key statistics

200-day average
201.17
Enterprise value
182.21B
PEG ratio
1.30
Price / sales
6.05
Price / book
2.89
Payout ratio
25.17%
Revenue growth
8.30%
Free cash flow
4.75B
Total cash
5.68B
Total debt
27.78B
Return on equity
8.19%
Short % of float
1.33%

Fundamental scorecard

17 of 25 checks passed on DHR’s reported financials

ValueGrowthProfitabilityHealthDividend

17of 25 checks passed

  • Value 3 of 5
  • Growth 3 of 5
  • Profitability 3 of 5
  • Financial health 4 of 5
  • Dividend 4 of 5

Statements to Sep 25, 2026.

Financials — quick view

All financials
DHR Revenue — quarterly 6.55B
DHR Net income — quarterly 1.24B
DHR EPS — quarterly 1.75

Earnings

DHR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Jan 27, 2027Dec 25, 20262.49———
Oct 21, 2026Sep 25, 20261.922.11+0.19+9.90%
Jul 21, 2026Jun 26, 20261.851.94+0.09+4.86%
Apr 21, 2026Mar 27, 20261.942.06+0.12+6.19%
Jan 28, 2026Dec 31, 20252.162.23+0.07+3.24%
Oct 21, 2025Sep 26, 20251.721.89+0.17+9.88%

Upgrades / downgrades

DHR analyst upgrades and downgrades
DateFirmActionFromTo
Oct 22, 2026CitigroupmainBuyBuy
Oct 22, 2026BarclaysmainOverweightOverweight
Oct 22, 2026JP MorganmainOverweightOverweight
Oct 22, 2026TD CowenmainBuyBuy
Oct 22, 2026StifelmainBuyBuy
Oct 22, 2026BairdmainOutperformOutperform

About Danaher Corporation

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
danaher.com

News

Your note

Sign in to keep a note on DHR — it syncs with the Stock Master app.

Insider holders

DHR insider holders
InsiderRelationLatest transactionDateShares held
BLAIR RAINER MChief Executive OfficerSaleAug 20, 20260
COMAS DANIEL LDirectorStock Award(Grant)Nov 12, 202668,550
FILLER LINDADirectorConversion of Exercise of derivative securityJul 14, 202648,419
GUTIERREZ-RAMOS JOSE-CARLOSOfficerStock Award(Grant)Aug 3, 202632,495
RALES MITCHELL POfficer and DirectorStock Award(Grant)Aug 3, 202627,509,900
RALES STEVEN MChairman of the BoardStock Award(Grant)Aug 3, 202634,626,700

Institution ownership

DHR institution ownership
Holder% heldSharesValueReported
Blackrock Inc.7.67%53,976,14311.88BSep 29, 2026
Vanguard Capital Management LLC5.85%41,190,8989.07BSep 29, 2026
FMR, LLC5.50%38,707,5398.52BSep 29, 2026
State Street Corporation4.06%28,547,1736.29BSep 29, 2026
Capital International Investors2.58%18,151,4084.00BSep 29, 2026
Capital Research Global Investors2.27%15,995,8843.52BSep 29, 2026

Fund ownership

DHR fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.87%20,222,9234.45BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.32%16,324,1983.59BJun 29, 2026
WASHINGTON MUTUAL INVESTORS FUND1.23%8,680,0621.91BSep 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.19%8,337,0211.84BSep 29, 2026
Fidelity Contrafund1.17%8,247,1021.82BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.16%8,131,0211.79BSep 29, 2026